PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8542158

Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients.

S A Kharitonov·D H Yates·P J Barnes
View original source ↗Export metadata ↓

Abstract

Exhaled nitric oxide (NO) is elevated in untreated patients with asthma but not in patients treated with inhaled glucocorticoids. This may reflect an inhibitory effect of glucocorticoids on the induction of the enzyme NO synthase in the respiratory tract. We have now studied the effect of an inhaled glucocorticoid (budesonide 800 micrograms twice daily via a dry powder delivery system for 3 wk) on exhaled NO in 11 patients with mild asthma in a double-blind crossover randomized-order placebo-controlled study. Exhaled NO was reduced from a baseline value of 203 +/- 29 parts per billion (ppb) to 120 +/- 26 ppb after 3 wk of treatment (p < 0.01), whereas there was no change after a matched placebo (169 +/- 20 at baseline compared with 184 +/- 16 ppb after 3 wk). A significant and progressive fall in exhaled NO was found from 1 to 3 wk. There was no significant change in FEV1 after inhaled steroids (although mean FEV1 was 92% predicted normal at baseline), although there was a reduction in airway responsiveness to methacholine (approximately 2.5 doubling dilutions). These results add further support to the view that the elevated levels of exhaled NO in asthma may derive from induction of an inducible isoform of NO synthase and indicate that exhaled NO may be a useful way of monitoring the anti-inflammatory effects of glucocorticoids and other anti-inflammatory treatments in asthma.

Explore related subjects

Administration, InhalationAdministration, TopicalAdultAerosolsAnti-Inflammatory AgentsAsthmaBreath TestsBronchodilator AgentsBudesonideCross-Over StudiesDouble-Blind MethodFemaleGlucocorticoidsHumansLuminescent MeasurementsMaleMonitoring, PhysiologicNitric OxidePlacebosPowdersPregnenedionesClinical TrialComparative StudyControlled Clinical TrialJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S A Kharitonov, D H Yates, P J Barnes. 1996. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients.. https://doi.org/10.1164/ajrccm.153.1.8542158

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1997

Effect of nitrous oxide on cerebral blood velocity while reclining and standing.

Cerebral blood velocity (CBV) (measured with transcranial Doppler, TCD) and other physiological and rating scale indices were measured before, during, and after inhaling a mixture of 40% nitrous oxide/oxygen and 40% nitrogen/oxygen, given during two separate visits in 7 normal male volunteers. During nitrous oxide/oxygen but not nitrogen/oxygen inhalation, CBV and euphoria increased significantly with minimal changes in other physiological indices except an increase in pulse rate after nitrous oxide/oxygen. In another 7 male volunteers, similar measurements were obtained while lying down and standing up during nitrous oxide/oxygen mixture and nitrogen/oxygen mixture inhalations, given during two separate visits. Nitrous oxide/oxygen inhalation produced significant CBV increase, which showed nonsignificant decrease of no clinical significance during standing up. There were no significant postural changes in blood pressure. Standing up during nitrous oxide/oxygen inhalation was associated with significant though mild dizziness.

Administration, Inhalation↗
PubMed1997

In vitro and in vivo cytotoxic effects of nitric oxide on metastatic cells.

It has been reported that nitric oxide (NO) is tumoricidal in vitro and inhalation of NO is effective for the therapy of pulmonary hypertension. However, little attention has been addressed to the effects of inhaled NO on tumors in the lung. In the present study cytotoxic effects of NO have been investigated both in vitro and in vivo using metastatic cell lines. Viabilities of both B16 melanoma and Lewis lung carcinoma cells were decreased in the presence of S-nitroso-N-acetyl-DL-penicillamine (SNAP) in vitro and the cytotoxicity of SNAP was reduced dose-dependently by NO radical scavenger, oxyhemoglobin. To examine in vivo tumoricidal activity of NO, mice were exposed to 10-80 ppm NO gas after intravenous injection of both tumor cell lines. Intravenous injection of both cell lines produced metastatic tumor colonies in the mouse lung. However, inhaled NO did not reduce the tumor colony formation in the lung. The increase in NO concentration was accompanied by elevation of concomitant nitric dioxide concentration in exposure chambers and exposure to higher concentration of NO appeared to enhance tumor colony formation in the lung.

Administration, Inhalation↗
PubMed1997

A concentrated and stable aerosol formulation of cationic lipid:DNA complexes giving high-level gene expression in mouse lung.

Advances in gene therapy vectors and techniques hold promise for treatment of many inherited and acquired diseases. For lung indications, especially those involving the epithelium, delivery of the gene therapy vehicle ideally will involve the use of an aerosol. Aerosol delivery of transgenes using cationic lipids is currently limited by the ability to generate highly concentrated formulations of lipid:DNA complexes that are stable and retain their activity following aerosolization. We have examined many of the variables inherent in aerosolizing cationic lipid gene delivery vehicles and have devised a new formulation that incorporates small amounts of a polyethylene glycol-containing lipid. This formulation has allowed the preparation of concentrated dispersions of cationic lipid:plasmid DNA (pDNA) complexes (> 20 mM pDNA) at approximately 10-fold higher concentrations than previously reported. Most of the pDNA in these formulations was bound to the lipid component and thereby protected from nebulizer-induced shearing; the pDNA also maintained full biological activity both in vitro and in vivo. This new formulation thus represents a significant improvement over current methods to prepare concentrated, active cationic lipid gene delivery vectors, and provides a new tool with which to test gene transfer to the lung.

Administration, Inhalation↗